Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209 is registered in ClinicalTrials.gov with Asklepion Pharmaceuticals, LLC as lead sponsor.

NCT NCT05253209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
Lead sponsor
Asklepion Pharmaceuticals, LLC
Phase
Phase 3
Overall status
Terminated
Start date
June 29, 2022
Completion date
May 10, 2024
Enrollment
64 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

atrioventricular septal defect, primum atrial septal defect, ventricular septal defect